AR046311A1 - Derivados de 1,2,4 tiadiazoles. composiciones farmaceuticas. - Google Patents
Derivados de 1,2,4 tiadiazoles. composiciones farmaceuticas.Info
- Publication number
- AR046311A1 AR046311A1 ARP040103979A ARP040103979A AR046311A1 AR 046311 A1 AR046311 A1 AR 046311A1 AR P040103979 A ARP040103979 A AR P040103979A AR P040103979 A ARP040103979 A AR P040103979A AR 046311 A1 AR046311 A1 AR 046311A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- cycloalkyl
- pharmaceutical compositions
- tiadiazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
El presente se refiere a composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto de fórmula (1), en la cual: m es 1, 2 ó 3; n es 0 ó 1; X es S u O; Y es S, CH2 u O; R1 y R2 se seleccionan en forma independiente de H, alquilo C1-4, alcoxi C1-3, halo y -NRaRb, donde cada uno de Ra y Rb se seleccionan independiente H y alquilo C1-4; cada uno de R3 y R4 se selecciona independientemente de H, halo, ciano, alquilo C1-4, alcoxi C1-3 y NRcRd, donde cada uno de Rc y Rd se selecciona en forma independientemente de H y alquilo C1-4; y donde al menos uno de R3 y R4 no es H; y cada uno de R5 y R6 se selecciona independientemente de H, alquilo C1-5, alcoxi C1-5, cicloalquilo C3-5, (cicloalquil-C3-5)-alquilo(C1-3), y NReRf, donde cada uno de Re y Rf se selecciona independientemente de H y alquilo C1-4; o R5 y R6 juntos forman espiro-cicloalquilo(C3-6), o espiro-heterociclilo de 5 ó 6 miembros que presenta entre 1 y 3 heteroátomos seleccionados de O, S y N; y cada uno de R7 y R8 se selecciona independientemente de H, alquilo C1-5, y cicloalquilo C3-5; o una sal de los mismos aceptable para uso farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51656103P | 2003-10-31 | 2003-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046311A1 true AR046311A1 (es) | 2005-11-30 |
Family
ID=34549548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103979A AR046311A1 (es) | 2003-10-31 | 2004-10-29 | Derivados de 1,2,4 tiadiazoles. composiciones farmaceuticas. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US7015329B2 (es) |
| EP (1) | EP1684752B1 (es) |
| JP (1) | JP2007527416A (es) |
| KR (1) | KR20060109925A (es) |
| CN (1) | CN1897939A (es) |
| AR (1) | AR046311A1 (es) |
| AT (1) | ATE362367T1 (es) |
| AU (1) | AU2004285530A1 (es) |
| BR (1) | BRPI0416106A (es) |
| CA (1) | CA2544317A1 (es) |
| CR (1) | CR8377A (es) |
| DE (1) | DE602004006529T2 (es) |
| EA (1) | EA009804B1 (es) |
| EC (1) | ECSP066536A (es) |
| ES (1) | ES2287786T3 (es) |
| IL (1) | IL175310A0 (es) |
| NO (1) | NO20062511L (es) |
| TW (1) | TW200528438A (es) |
| UA (1) | UA84035C2 (es) |
| WO (1) | WO2005041959A1 (es) |
| ZA (1) | ZA200604420B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1667964E (pt) | 2003-09-19 | 2009-09-02 | Janssen Pharmaceutica Nv | Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos |
| US7015329B2 (en) * | 2003-10-31 | 2006-03-21 | Janssen Pharmaceutica N. V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| WO2006042245A1 (en) * | 2004-10-11 | 2006-04-20 | Dr. Reddy's Laboratories Ltd. | Novel isoxazole compounds having ppar agonist activity |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| UY30288A1 (es) * | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
| CA2663121C (en) | 2006-09-08 | 2016-01-19 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
| JP5864077B2 (ja) | 2006-09-08 | 2016-02-17 | ロード アイランド ホスピタル | アルコール誘発性肝疾患の治療、予防および回復 |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| CA2684059C (en) | 2007-04-11 | 2016-07-12 | Omeros Corporation | Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| ES2423793T3 (es) | 2008-05-26 | 2013-09-24 | Genfit | Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias |
| CN103140483B (zh) | 2010-07-15 | 2015-06-24 | 拜耳知识产权有限责任公司 | 作为杀虫剂的新杂环化合物 |
| CA2809958A1 (en) | 2010-08-31 | 2012-03-08 | Snu R & Db Foundation | Use of the fetal reprogramming of a ppar ? agonist |
| WO2012052412A1 (de) | 2010-10-22 | 2012-04-26 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| EP2841448A1 (en) | 2012-04-26 | 2015-03-04 | Bristol-Myers Squibb Company | Par4 agonist peptides |
| HUE060743T2 (hu) | 2012-04-26 | 2023-04-28 | Bristol Myers Squibb Co | Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére |
| CN118359543A (zh) * | 2023-01-18 | 2024-07-19 | 哈尔滨三联药业股份有限公司 | 五元杂环类化合物及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| US6242493B1 (en) * | 1998-03-13 | 2001-06-05 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| WO1999065881A1 (en) | 1998-06-19 | 1999-12-23 | Nissan Chemical Industries, Ltd. | Heterocyclic compounds as hypoglycemic agents |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| ES2261202T3 (es) | 1999-04-28 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de acido de triarilo como ligandos para el receptor ppar. |
| CA2382966A1 (en) * | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| ATE542805T1 (de) * | 2000-08-11 | 2012-02-15 | Nippon Chemiphar Co | Ppar-delta aktivatoren |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| DE60336264D1 (de) | 2002-12-20 | 2011-04-14 | Bayer Pharmaceuticals Corp | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung |
| US7015329B2 (en) * | 2003-10-31 | 2006-03-21 | Janssen Pharmaceutica N. V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
-
2004
- 2004-10-28 US US10/975,785 patent/US7015329B2/en not_active Expired - Fee Related
- 2004-10-28 CA CA002544317A patent/CA2544317A1/en not_active Abandoned
- 2004-10-28 AU AU2004285530A patent/AU2004285530A1/en not_active Abandoned
- 2004-10-28 EA EA200600878A patent/EA009804B1/ru not_active IP Right Cessation
- 2004-10-28 EP EP04796767A patent/EP1684752B1/en not_active Expired - Lifetime
- 2004-10-28 BR BRPI0416106-8A patent/BRPI0416106A/pt not_active IP Right Cessation
- 2004-10-28 ES ES04796767T patent/ES2287786T3/es not_active Expired - Lifetime
- 2004-10-28 AT AT04796767T patent/ATE362367T1/de not_active IP Right Cessation
- 2004-10-28 UA UAA200605139A patent/UA84035C2/ru unknown
- 2004-10-28 JP JP2006538316A patent/JP2007527416A/ja not_active Withdrawn
- 2004-10-28 KR KR1020067010610A patent/KR20060109925A/ko not_active Application Discontinuation
- 2004-10-28 WO PCT/US2004/036028 patent/WO2005041959A1/en active IP Right Grant
- 2004-10-28 CN CNA2004800382161A patent/CN1897939A/zh active Pending
- 2004-10-28 DE DE602004006529T patent/DE602004006529T2/de not_active Expired - Fee Related
- 2004-10-29 TW TW093132849A patent/TW200528438A/zh unknown
- 2004-10-29 AR ARP040103979A patent/AR046311A1/es not_active Application Discontinuation
-
2005
- 2005-11-15 US US11/274,656 patent/US7498351B2/en not_active Expired - Fee Related
-
2006
- 2006-04-27 IL IL175310A patent/IL175310A0/en unknown
- 2006-04-28 EC EC2006006536A patent/ECSP066536A/es unknown
- 2006-05-02 CR CR8377A patent/CR8377A/es unknown
- 2006-05-30 ZA ZA200604420A patent/ZA200604420B/en unknown
- 2006-05-31 NO NO20062511A patent/NO20062511L/no not_active Application Discontinuation
-
2009
- 2009-01-23 US US12/358,703 patent/US20090131489A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP066536A (es) | 2006-12-20 |
| EA009804B1 (ru) | 2008-04-28 |
| CR8377A (es) | 2008-11-24 |
| BRPI0416106A (pt) | 2007-01-02 |
| ATE362367T1 (de) | 2007-06-15 |
| EP1684752B1 (en) | 2007-05-16 |
| EP1684752A1 (en) | 2006-08-02 |
| CN1897939A (zh) | 2007-01-17 |
| KR20060109925A (ko) | 2006-10-23 |
| UA84035C2 (ru) | 2008-09-10 |
| NO20062511L (no) | 2006-07-27 |
| US20050096362A1 (en) | 2005-05-05 |
| IL175310A0 (en) | 2006-09-05 |
| ZA200604420B (en) | 2007-10-31 |
| DE602004006529D1 (de) | 2007-06-28 |
| JP2007527416A (ja) | 2007-09-27 |
| US7015329B2 (en) | 2006-03-21 |
| DE602004006529T2 (de) | 2008-01-31 |
| US20090131489A1 (en) | 2009-05-21 |
| EA200600878A1 (ru) | 2006-10-27 |
| ES2287786T3 (es) | 2007-12-16 |
| WO2005041959A1 (en) | 2005-05-12 |
| US7498351B2 (en) | 2009-03-03 |
| TW200528438A (en) | 2005-09-01 |
| US20060074246A1 (en) | 2006-04-06 |
| AU2004285530A1 (en) | 2005-05-12 |
| CA2544317A1 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046311A1 (es) | Derivados de 1,2,4 tiadiazoles. composiciones farmaceuticas. | |
| CO5611128A2 (es) | Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR048375A1 (es) | Indazol-o-glucosidos sustituidos | |
| AR059178A1 (es) | Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. | |
| AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| CO6150140A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
| CO6190512A2 (es) | Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR044629A1 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos. | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR041739A1 (es) | Compuestos derivados -3,4-dihidro-1h-pirimido[4,5-d]pirimidin-2-ona y con actividad antiproliferativa. | |
| AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR053774A1 (es) | Derivados de sulfonilbencimidazol. composiciones farmaceuticas. | |
| PE20211703A1 (es) | Compuesto derivado heterotriciclico novedoso y uso del mismo | |
| AR070345A1 (es) | (dihidro ) pirrolo (2,1-a) isoquinolinas | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR069230A1 (es) | Inhibidores de peptido desformilasa | |
| AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
| AR061134A1 (es) | Derivados de tioxantina | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| AR056645A1 (es) | Compuestos de urea sustituida inhibidores de enzimas chk1 . | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |